ABINGDON, England, December 3, 2015 /PRNewswire/ --
OBN - the membership organisation supporting the UK's emerging life sciences companies - announced today that it has appointed Dr John Harris as CEO, replacing Ross Sommerville who has been supporting OBN as Interim CEO since June 2015. Dr Harris' extensive experience of the sector and ability to grow organisations made him the ideal candidate to take OBN forward.
Currently Dr Harris is delivering Business and Export advice to UK Trade & Industry clients, assisting Life Science companies on growth strategies both domestically and abroad. His most recent appointment was Managing Partner of Qube Associates, a specialist consultancy focusing on science-based SME's.
Previous appointments include Managing Director of IPS Specials / Vertical Pharma Ltd (a cGMP, MHRA licensed manufacturer of 'Special' compounded pharmaceuticals), Managing Director of Key Organics Ltd (a leading manufacturer of chemical intermediates), Managing Director of Synerga Ltd (a start-up drug discovery venture) and Chief Executive Officer of TraceTag International Ltd (a biotech company specialising in the research, development and marketing of hi-tech diagnostics).
Dr Harris holds a BSc (Hons) in Biology from the University of Salford, a PhD in Plant Pathology / Biochemistry from the University of Southampton and a MBA from the University of Surrey.
Dr John Harris commenting on his new appointment: "I am delighted to be joining OBN as CEO; it has a fantastic purpose and a very impressive membership base. I am thrilled to be given this role and very much looking forward to working with OBN's member companies, its experienced team and a range of stakeholders to continue growing a vibrant life sciences sector in the UK."
David Laskow-Pooley, Chairman of OBN, said: "We are very excited and pleased to have Dr Harris join OBN to continue and lead our work supporting the development of emerging life sciences companies in the UK. Dr Harris will bring enormous skills and knowledge to continue our growth."
He added: "I would also like to thank Ross Sommerville, who has been Interim CEO of OBN. He has done an excellent job in steering the organisation through this transition period since June. We wish him every success as he continues in his business consulting and executive coaching role."
Dr Harris will commence his role with OBN on Monday 21st December 2015.
Photos available upon request.
OBN is the Membership organisation supporting and bringing together the UK's emerging life sciences companies, corporate partners and investors. Our 370-plus member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland and benefit from our networking, partnering, purchasing, advising and advocacy activities. OBN is best known for its delivery of BioTrinity (April 25-27, 2016), Europe's leading life sciences investment and biopartnering conference.
Further information about OBN's tailored networking and partnering events, purchasing consortium, advice, consultancy services and advocacy activities is available on OBN's website http://www.obn.org.uk
David Laskow-Pooley, Chairman, OBN
Citigate Dewe Rogerson